enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / May 12, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr.